Archived
This content is available here strictly for research, reference, and/or recordkeeping and as such it may not be fully accessible. If you work or study at University of Kentucky and would like to request an accessible version, please use the SensusAccess Document Converter.
US Patent Number
7588764
Publication Date
9-15-2009
Abstract
Non-denatured, recombinant human immunodeficiency virus (HIV) Tat that is free of bacterial RNA and endotoxin is employed in an anti-HIV vaccine. A process of producing the recombinant Tat protein includes steps for removing bacterial RNA from the recombinant Tat and for removing endotoxin from the recombinant Tat protein. A Tat-adsorbed nanoparticle formulation and method of making the same. A method of vaccinating against and/or treating HIV infection comprises administering to a subject in need of such vaccination or treatment an immune-response inducing effective amount of the recombinant Tat protein.
Assignees
University of Kentucky Research Foundation, Lexington, KY (US)
Application Number
10/506,408
Filing Date
02/27/2003
Recommended Citation
Mumper, Russell J.; Woodward, Jerold; Cui, Zhengrong; and Nath, Avindra, "Compositions Comprising Human Immunodeficiency Virus Tat Adsorbed to the Surface of Anionic Nanoparticles" (2009). Pharmaceutical Sciences Faculty Patents. 123.
https://uknowledge.uky.edu/ps_patents/123
